50 search results for: symposium

Considerations for Disease Modification in AD
Dermatology
Considerations for Disease Modification in AD
expert video

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.

View more
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
Type 2 Inflammation
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
expert video

Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.

View more
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
Dermatology
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
expert video

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

View more
Epidemiology and Pathophysiology of AD in Children
Dermatology
Epidemiology and Pathophysiology of AD in Children
expert video

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses the epidemiology of AD in children and the role of type 2 cytokines in driving the pathophysiology of the disease

View more
IL-4 Contributes to Systemic Type 2 Inflammation in AD
Dermatology
IL-4 Contributes to Systemic Type 2 Inflammation in AD
expert video

In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.

View more
Key Treatment Considerations for Management of Atopic Dermatitis in Children
Dermatology
Key Treatment Considerations for Management of Atopic Dermatitis in Children
expert video

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the key considerations for management of AD that is uncontrolled with topical therapies in children and the criteria to determine whether a patient is indicated for systemic therapy

View more
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD
Dermatology
Prevalence of Food Allergy and Other Atopic Comorbidities in Children With AD
expert video

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the prevalence of food sensitization and food allergy in pediatric patients with AD, clarifying the difference between the two. Dr Boguniewicz also discusses the prevalence of other atopic comorbidities in children with AD

View more
Identification and Management of AD Uncontrolled With Topical Therapies in Children
Dermatology
Identification and Management of AD Uncontrolled With Topical Therapies in Children
expert video

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment

View more
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
Dermatology
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
expert video

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
On Demand
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
Dermatology
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
expert video

In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.

View more
ADVENT in Orlando, FL 2025
Congress
7
March
2025
Congress
ADVENT in Orlando, 2025

Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.